Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

RSS icon

Siemens’ PETNET Solutions to Offer PET Prostate Tracer for Clinical Trials

In an effort to support positron emission tomography (PET) imaging techniques for the diagnosis and treatment of prostate cancer, Siemens’ PETNET Solutions, a wholly owned subsidiary of Siemens Healthcare, will provide clinical researchers in the greater New York City area with access to Gallium-68-Labelled Prostate-Specific Membrane Antigen (68Ga-labelled PSMA). 

Argonne lab confirms commercial method of Mo-99 production

The U.S. Department of Energy’s Argonne National Laboratory in Illinois has demonstrated the successful production, separation and purification of molybdenum-99 (Mo-99) using a process developed in a public-private partnership with SHINE Medical Technologies.

SNMMI: Follow-up PET/CT adds value in non-Hodgkin lymphoma management

Post-treatment PET/CT can help diagnose relapses of aggressive non-Hodgkin lymphoma (NHL) cases and spur additional treatment, according to research presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2015 annual meeting in Baltimore.

SNMMI: Whole-body dynamic PET imaging offers broader view of cancer

A newly developed technique leverages integrin imaging and multi-bed-position dynamic PET acquisition to create advanced whole-body parametric maps, which could help evaluate tumors and metastases throughout the body, according to research presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2015 annual meeting in Baltimore.

UCLA’s Phelps, PET inventor, receives Nuclear Pioneer Award from SNMMI

Michael E. Phelps, PhD, professor and chair of the University of California, Los Angeles (UCLA), Department of Molecular & Medical Pharmacology, received the Georg Charles de Hevesy Nuclear Pioneer Award from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) for his work in the field, including his role in the development of the PET scanner.

Siemens Expanding Capabilities, Increasing Productivity at SNMMI 2015

t the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 6-10 at the Baltimore Convention Center, Siemens Healthcare debuts new technologies designed to expand the capabilities and improve the productivity of molecular imaging. Symbia Evo,™ Siemens’ new single-photon emission computed tomography (SPECT) system, boosts user productivity, providing facilities with more time to plan treatment schedules, personalize studies, serve additional patients, and improve workflow efficiency. 

Siemens’ PETNET Solutions inks deal to distribute U.K.-based company’s prostate PET agent

Siemens’ PETNET Solutions has entered into an agreement with U.K.-based Blue Earth Diagnostics to secure exclusive commercial manufacturing and distribution of fluciclovine (18F), an investigational PET radiopharmaceutical, once the agent receives FDA approval.

VeriTeQ Awarded New U.S. Patent for Wireless Molecular Sensor System and Process

VeriTeQ Corporation ("VeriTeQ" or the "Company") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it has been awarded a U.S. Patent for Wireless Molecular Sensor System and Process. The Company intends to utilize the patent in the development of future bio-sensing microchip applications, initially focused on its radiation dose measurement technologies used during cancer treatment. 

Displaying 537 - 544 of 3687

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.